Literature DB >> 15542719

Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity.

Dean E Dluzen1, Janet L McDermott.   

Abstract

The gonadal steroid hormone estrogen (E) may play an important role in sex differences in methamphetamine (MA)-induced neurotoxicity of the nigrostriatal dopaminergic (NSDA) system because E can serve as a neuroprotectant in female, but not male, mice. Gonadal steroid hormones also exert important organizational/developmental effects upon the brain at critical developmental periods. In Part 1 we assessed whether organizational (neonatal) or developmental (prepubertal) effects of gonadal steroids would alter gender/E-dependent neuroprotection of MA-induced NSDA neurotoxicity. Attempts to feminize male mice by gonadectomy at either the neonatal or prepubertal period failed to enable E to function as a neuroprotectant within the adult male mouse. Attempts to masculinize the female by testosterone administration at the neonatal period did not abolish the capacity for E to function as a neuroprotectant. However, prepubertal gonadectomy of female mice did disrupt E's capacity to serve as a neuroprotectant. These results suggest that genetic sex may prove the primary determinant for the sex differences observed in response to MA-induced NSDA neurotoxicity. In Part 2 we examined whether gender differences in response to MA-induced NSDA neurotoxicity would interact with a specific genetic alteration in a neurotrophic factor, brain-derived neurotrophic factor (BDNF). Female and male mice that were either deficient (+/- BDNF) or overexpressing (DBH:BDNF+) BDNF were treated with MA. Sex differences in MA-induced NSDA neurotoxicity remained present in +/- BDNF mice and were less severe as compared with their wild-type controls. A similar result was obtained in mice that overexpress BDNF, with female and mutant mice showing less NSDA neurotoxicity. In both BDNF-deficient mice and mice that overexpress BDNF, the relative degree of MA-induced NSDA neurotoxicity was lower in males. Taken together, these results suggest that a selective alteration in BDNF expression offers some neuroprotective potential against MA-induced NSDA neurotoxicity, and the relative degree of this neuroprotection may interact with the gender of the subject.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542719     DOI: 10.1196/annals.1316.026

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

2.  Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.

Authors:  Keith G Heinzerling; Steven Shoptaw
Journal:  Gend Med       Date:  2012-03-23

Review 3.  Estrogen-BDNF interactions: implications for neurodegenerative diseases.

Authors:  Farida Sohrabji; Danielle K Lewis
Journal:  Front Neuroendocrinol       Date:  2006-10-27       Impact factor: 8.606

4.  17β-estradiol protects dopaminergic neurons in organotypic slice of mesencephalon by MAPK-mediated activation of anti-apoptosis gene BCL2.

Authors:  Shuyan Wang; Ping Ren; Xiaobo Li; Yunqian Guan; Yu Alex Zhang
Journal:  J Mol Neurosci       Date:  2011-02-16       Impact factor: 3.444

5.  The human testis-determining factor SRY localizes in midbrain dopamine neurons and regulates multiple components of catecholamine synthesis and metabolism.

Authors:  Daniel P Czech; Joohyung Lee; Helena Sim; Clare L Parish; Eric Vilain; Vincent R Harley
Journal:  J Neurochem       Date:  2012-06-08       Impact factor: 5.372

6.  Profile of executive and memory function associated with amphetamine and opiate dependence.

Authors:  Karen D Ersche; Luke Clark; Mervyn London; Trevor W Robbins; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2006-05       Impact factor: 7.853

7.  Comparison of brain white matter hyperintensities in methamphetamine and methadone dependent patients and healthy controls.

Authors:  Abdulrasool Alaee; Mehran Zarghami; Samaneh Farnia; Mohammad Khademloo; Talayeh Khoddad
Journal:  Iran J Radiol       Date:  2014-05-15       Impact factor: 0.212

8.  Role of calbindin-D28K in estrogen treatment for Parkinson's disease.

Authors:  Chunhua Wang; Chao Jiang; Honghua Yuan; Chenghua Xiao; Dianshuai Gao
Journal:  Neural Regen Res       Date:  2013-03-15       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.